Literature DB >> 17367814

Multiple sclerosis: is there neurodegeneration independent from inflammation?

Hans Lassmann1.   

Abstract

Clinical and magnetic resonance imaging studies in multiple sclerosis have recently suggested that neurodegenerative events may take place in multiple sclerosis brains, which occur independently from inflammation. Here we summarize the results from recent pathological studies, which show, that inflammation is invariably present at all stages and in all forms of the disease. However, the patterns of inflammation differ between different disease stages. This may in part explain, why anti-inflammatory or immunosuppressive treatments fail in progressive multiple sclerosis.

Entities:  

Mesh:

Year:  2007        PMID: 17367814     DOI: 10.1016/j.jns.2006.08.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  33 in total

1.  Normal-appearing white matter permeability distinguishes poor cognitive performance in processing speed and working memory.

Authors:  A Eilaghi; A Kassner; I Sitartchouk; P L Francis; R Jakubovic; A Feinstein; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2013-05-30       Impact factor: 3.825

2.  Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective.

Authors:  M Filippi; M A Rocca; F Barkhof; R Bakshi; F Fazekas; O Khan; D Pelletier; A Rovira; J Simon
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-03       Impact factor: 3.825

Review 3.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.

Authors:  Eldar Eftekhari; Seyed-Parsa Hojjat; Rita Vitorino; Timothy J Carroll; Charles Grady Cantrell; Liesly Lee; Matthew W Taylor; Sarah A Morrow; Haddas Benhabib; Richard I Aviv; Andrea Kassner
Journal:  Neuroradiology       Date:  2017-06-16       Impact factor: 2.804

5.  Multi-modal quantitative MRI investigation of brain tissue neurodegeneration in multiple sclerosis.

Authors:  Khader M Hasan; Indika S Walimuni; Humaira Abid; Jerry S Wolinsky; Ponnada A Narayana
Journal:  J Magn Reson Imaging       Date:  2012-01-12       Impact factor: 4.813

Review 6.  Sodium MRI of multiple sclerosis.

Authors:  Maria Petracca; Lazar Fleysher; Niels Oesingmann; Matilde Inglese
Journal:  NMR Biomed       Date:  2015-04-06       Impact factor: 4.044

7.  CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis.

Authors:  Yingru Liu; Yoshio Bando; David Vargas-Lowy; Wassim Elyaman; Samia J Khoury; Tao Huang; Karin Reif; Tanuja Chitnis
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

Review 8.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

9.  Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.

Authors:  Hormoz Ayromlou; Hadi Mohammad-Khanli; Mohammad Yazdchi-Marandi; Reza Rikhtegar; Sina Zarrintan; Samad Ej Golzari; Kamyar Ghabili
Journal:  Malays J Med Sci       Date:  2013-07

10.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.